News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No news items were published in the past hour, leaving no fresh headlines to move markets.
  • Equity and bond markets trading quietly without headline-driven flows to change risk pricing.
  • No macro releases, central bank comments, or economic data arrived in the last hour.
  • No geopolitical events reported that would affect oil, safe-haven demand, or commodity prices.
  • No corporate earnings, M&A, or major corporate actions were announced in the past hour.
  • Expect muted volatility and liquidity until the next scheduled data or breaking news item.

Latest Articles

Celsius Holdings Shares Inch Higher After CEO Adds to Stake

Celsius Holdings Shares Inch Higher After CEO Adds to Stake

Celsius Holdings Inc. stock moved up roughly 2% in premarket trading on Friday after Chief Executive Officer John Fieldly reported buying 18,000 shares of common stock. The Form 4 filing with the Securities and Exchange Commission shows a weighted average purchase price of $27.4357 per share, with the transactions executed in a narrow range. After …

Northrop Grumman: Tactical Long on a Dip, But I'll Remain Largely in Cash

Northrop Grumman: Tactical Long on a Dip, But I'll Remain Largely in Cash

Northrop Grumman (NOC) sits on solid cash flow, double-digit ROE and an $73.7B market cap, but the stock is off its 52-week highs and showing bearish technical momentum. My base preference is to stay in cash. For traders who want exposure, I outline a mid-term (45 trading days) tactical long: enter $490.00, stop $470.00, target $565.00 — a defined-…

Exelixis Shares Slip After FDA Pushes Back Zanzalintinib Review

Exelixis Shares Slip After FDA Pushes Back Zanzalintinib Review

Exelixis Inc. shares declined in premarket trading after the FDA extended the review window for the company’s new drug application for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer. The agency said the extension followed submission of updated safety and efficacy data that it classified as a major amendment, moving …

U.S. Consumer Inflation Accelerates in August as Gas Prices Rebound

U.S. Consumer Inflation Accelerates in August as Gas Prices Rebound

U.S. consumer prices picked up in August, driven in part by a rebound in gasoline costs, pushing the Consumer Price Index up 0.4% for the month and 3.4% year-on-year. Core CPI, which excludes food and energy, rose 0.3% in August and 2.4% on an annual basis. A stronger Producer Price Index and solid employment figures have increased market expectati…

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials

Quantum BioPharma Ltd., trading on NASDAQ as QNTM, announced FDA clearance to initiate phase 2 clinical trials of Lucid-MS, an innovative first-in-class drug candidate aimed at protecting and potentially repairing the myelin sheath in multiple sclerosis patients. The drug represents a novel approach distinct from existing treatments by attempting t…

Antelope Enterprise Holdings Limited Announces Pricing of $6.0 Million Convertible Promissory Note

Antelope Enterprise Holdings Limited Announces Pricing of $6.0 Million Convertible Promissory Note

Antelope Enterprise Holdings Limited announced the pricing of a $6.0 million convertible promissory note to Stratosphere Capital Management, bearing 8% interest with conversion options into common shares at a discounted price. The note has no fixed maturity date, features ownership limitations on conversion, and is intended to provide additional ca…

Draganfly Selected by Government of Canada to Supply Low-Cost Tactical ISR UAS to the Canadian Armed Forces

Draganfly Selected by Government of Canada to Supply Low-Cost Tactical ISR UAS to the Canadian Armed Forces

Draganfly Inc. has been awarded a five-year contract by the Government of Canada to supply Low-Cost Tactical Intelligence, Surveillance and Reconnaissance (ISR) Uncrewed Aircraft Systems (UAS) to the Canadian Armed Forces. The initial contract includes 100 systems with options to supply up to an additional 4,900 units. The contract includes support…

Bond and Watson Realty Corp. Team Up to Transform Personal Security for the Real Estate Industry in the US and Globally

Bond and Watson Realty Corp. Team Up to Transform Personal Security for the Real Estate Industry in the US and Globally

Our Bond, Inc. (NASDAQ: OBAI) has partnered with Watson Realty Corp., a major residential real estate brokerage in Florida and Georgia, to provide Bond’s AI-powered Preventative Personal Security platform to all 800 Watson agents companywide. This rollout coincides with REALTOR® Safety Month and aims to address safety concerns for real estate profe…

Petrobras: Reconfirming My Top Pick — Risk-Managed Entry into PBR

Petrobras: Reconfirming My Top Pick — Risk-Managed Entry into PBR

Petrobras (PBR) remains one of the most compelling income-and-value plays in energy: a $132.9B market-cap integrated oil company trading at a 5.3x P/E with a 5.7% dividend yield, mounting LNG optionality and renewed drilling activity in the Santos pre-salt. Momentum is constructive but stretched, so I’m advocating a risk-managed long with a clear e…

JPMorgan Pulls Back on Chewy, Citing Ongoing Macro Pressure on Organic Sales

JPMorgan Pulls Back on Chewy, Citing Ongoing Macro Pressure on Organic Sales

JPMorgan downgraded Chewy to Neutral from Overweight on Friday, pointing to persistent macroeconomic headwinds that are constraining the online pet retailer's organic growth even as the company shows operational progress. Analyst Doug Anmuth set a December 2027 price target of $24, rooted in roughly seven times his 2028 adjusted EBITDA forecast of …